Xlife Sciences Ltd. · SIX:XLS
Xlife Sciences — Investor Presentation (June 2026)
20 slides from Xlife Sciences's investor presentation, Jun 2, 2026
Slide 1: The Leading European Life Sciences Incubator and Accelerator
THE LEADING EUROPEAN LIFE SCIENCES INCUBATOR AND ACCELERATOR
Slide 2: Disclaimer
Disclaimer NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION WOULD BE UNLAWFUL The presentation has been prepared by Xlife Sciences Ltd. (“Xlife”, and together with its subsidiaries, the "Xlife
Slide 3: Company Overview
COMPANY OVERVIEW Xlife Sciences is a Swiss life sciences incubator and accelerator. 2019 1 ~5.77 M 50.2% LAUNCH STOCK EXCHANGE SHARES FREE FLOAT WITH 6 PROJECT COMPANIES SPARKS SEGMENT SIX SWISS EXCHANGE 5.767.572 SHARES WITH A NOMINAL 42,8% FOUNDERS, 7% MANAGEMENT SINCE FEBRUARY 2022, VALUE OF CHF
Slide 4: Business Model
BUSINESS MODEL Xlife Sciences supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. ~300 ~3-5 ~1.5 M ~500k INVENTION DISCLOSURES P.A. NEW PROJECT COMPANIES P.A. FINANCING POTENTIAL GRANTS WHERE WE ADD VALUE TO OUR PROJECT BREAKDOWN BY PROJECT
Slide 5: Investment Process
INVESTMENT PROCESS 4 3 EXIT 2 ACTIVE MANAGEMENT & SYNERGIES STRATEGY 1 BUSINESS EVALUATION & SCIENTIFIC ASSESSMENT INITIAL CONTACT & INVENTION DISCLOSURE Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I ir@xlifesciences.ch 4
Slide 6: Company Leadership
COMPANY LEADERSHIP Oliver R. Baumann Carl von Halem Dr. Alexander Zink Dr. Frank Plöger Christian Faber Beat Kläui Chief Executive Officer Chief Financial Chief Scientific MD Xlife Sciences Head of Legal & Head of Accounting MANAGEMENT Officer Officer USA Compliance and Taxes David L. Deck Désirée A
Slide 7: Key Focus Areas & Project Companies
KEY FOCUS AREAS & PROJECT COMPANIES TECHNOLOGY PLATFORMS BIOTECH & THERAPIES MEDICAL TECHNOLOGY ARTIFICIAL INTELIGENCE Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I ir@xlifesciences.ch 6
Slide 8: Selected Markets
SELECTED MARKETS METABOLIC / MEDICAL ONCOLOGY 3D-PRINTING DIAGNOSTICS OBESITY INFLAMMATION DEVICES CRO Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I ir@xlifesciences.ch 7
Slide 9: Portfolio
PORTFOLIO Our approach is to be in the driver seat. In over 50% of the new project companies, Xlife Sciences initiated the spin-off process directly from and with a university or research institution. INITIAL PROJECTS #6 SPIN-OFF #12 STRATEGIC #6 INDUSTRY JOINT VENTURE #3 25% EXITED 51% 100% 75% Lic
Slide 10: Project Stage
PROJECT STAGE T E C H N O L O G Y P L A T F O R M S ARTIFICIAL INTELLIGENCE XLIFE R&D POC EXIT XLIFE R&D POC EXIT 2021 2019 2019 2021 2019 2020 BIOTECH & THERAPIES MEDTECH & DIAGNOSTIC XLIFE R&D POC EXIT XLIFE R&D POC EXIT 2019 2019 2021 2019 2019 2019 2021 2019 2019 2022 2020 2019 2021 2020 2020 20
Slide 11: Presence
PRESENCE Xlife Sciences has a recent focus on DACH. In the course of various business development activities, the network has expanded into EMEA, Asia and the US. Lubeck Hamburg Bremen Boston Hannover Berlin Basel Zurich Abu Dhabi Dresden Bern New York City Frankfurt am Main Xlife Sciences AG I Tala
Slide 12: Business Partners
BUSINESS PARTNERS Xlife Sciences is built on long-term relationships and a growing network with inventors, leading universities and scientific institutions. Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I ir@xlifesciences.ch 11
Slide 13: Synergies
SYNERGIES Xlife Sciences synergies are a key driver of success. In the Xlife family, we live synergies. Many use cases and agreements have grown genuinely between our partners. PRECLINICAL AND ARTIFICIAL INTELLIGENCE SCREENING OF GMP & SOFTWARE CLINICAL DEVELOPMENT FUNCTIONAL ANTIBODIES MANUFACTURIN
Slide 14: Use Case – Veraxa Biotech AG
USE CASE – VERAXA BIOTECH AG There is a high need for safer, more effective cancer drugs Highly effective and cancer -specific therapies Make untreatable cancers treatable by using a toolbox of technologies 40% of cancer patients do not survive. Around 70% of cancer therapies fail in phase 2. Intole
Slide 15: ESG
ESG Our motivations is to integrate ESG in the whole group, to incorporate personal values and to make a positive impact. Please find here our current ESG-Report and Code of Conduct. DEFINE CODE OF PUBLISH ANALYSE INTEGRATION OF ESG-KPIs CONDUCT ESG- & IMPROVE GRI STANDARDS REPORT Xlife Sciences AG
Slide 16: Next Steps & Focus
NEXT STEPS & FOCUS Having built up the portfolio over the last few years, the main task now is to achieve successful exits with project companies, strengthen liquidity and continue to grow. CASH BRAND ENHANCE INCREASE STRENGTHEN EVENTS AWARENES PIPELINE LIQUIDITY TEAM S Xlife Sciences AG I Talacker
Slide 17: Value Inflection Points
VALUE INFLECTION POINTS We intend to carry out numerous projects as a license deal, trade sale or IPO. Below potential monetization events divided in two phases from near to mid-term future. NEAR-TERM MID-TERM E V E N T S M O N E T I Z A T I O N Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www
Slide 18: Why Xlife Sciences
WHY XLIFE SCIENCES With Xlife Sciences, we enable our shareholders to invest directly in a diversified early-stage life sciences portfolio in a liquid asset. LEAN AND COST- ACCESS TO A LIQUID DISCOUNTED EFFECTIVE DIVERSIFIED ASSET TRADE STRUCTURE PORTFOLIO Xlife Sciences AG I Talacker 35 I CH-8001 Z
Slide 19: Please Get in Touch
PLEASE GET IN TOUCH > Oliver R. Baumann > Carl v. Halem > Dr. Alexander Zink > Chief Executive Officer > Chief Financial Officer > Chief Scientific Officer > oliver.baumann@xlifesciences.ch > carl.halem@xlifesciences.ch > alexander.zink@xlifesciences.ch > +41 44 385 84 60 > +41 44 385 84 58 > +41 44
Slide 20: Where innovation leads to success
where innovation leads to success Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I Switzerland I +41 (0) 44 385 84 60 I www.xlifesciences.ch